{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:41:03Z","timestamp":1757619663300,"version":"3.44.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2023-00216446"],"award-info":[{"award-number":["RS-2023-00216446"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is known to compromise bone integrity, leading to an increased risk of fractures, which compromise the quality of life and increase mortality rates. This study investigated the incidence of fractures in MM patients and explored the association between fractures after MM diagnosis and mortality using the Korean National Health Insurance Service database. Fracture incidence was compared between MM patients (n\u2009=\u20099365) and 1:1 matched control group from general population. MM patients demonstrated a significantly higher cumulative incidence of fractures, and vertebral and hip fractures presented a particularly elevated hazard ratio (1.36 [95% CI 1.18\u20131.55] and 1.47 [95% CI 1.10\u20131.97], respectively). Furthermore, the presence of fracture within the first year of MM diagnosis were associated with increased mortality (any fracture\u2014HR 1.37 [95% CI 1.19\u20131.58]; vertebral fractures\u2014HR 1.39 [95% CI 1.19\u20131.63]; hip fractures\u2014HR 2.46 [95% CI 1.52\u20133.99]; upper limb fractures\u2014HR 1.94 [95% CI 1.32\u20132.87]). These results showed an increased risk of fracture and a correlation between fractures and increased mortality in MM patients, with hip fractures notably doubling the mortality risk. These findings underscore the importance of monitoring and managing bone health in MM patients to improve survival outcomes.<\/jats:p>","DOI":"10.1038\/s41598-025-09811-4","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T05:18:07Z","timestamp":1753593487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fractures incidence and its association on mortality in multiple myeloma patients: a nationwide cohort study (CAREMM-2105 study)"],"prefix":"10.1038","volume":"15","author":[{"given":"Jeonghoon","family":"Ha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seulji","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinseon","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongyoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunghoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"9811_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"9811_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3322\/caac.21252","volume":"64","author":"G Bianchi","year":"2014","unstructured":"Bianchi, G. & Anderson, K. C. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J. Clin. 64, 422\u2013444. https:\/\/doi.org\/10.3322\/caac.21252 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"9811_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian, D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin. Oncol. 43, 676\u2013681. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.004 (2016).","journal-title":"Semin. Oncol."},{"key":"9811_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4143\/crt.2021.291","volume":"53","author":"S Hong","year":"2021","unstructured":"Hong, S. et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat 53, 301\u2013315. https:\/\/doi.org\/10.4143\/crt.2021.291 (2021).","journal-title":"Cancer Res Treat"},{"key":"9811_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5045\/br.2021.2021187","volume":"56","author":"WJ Park","year":"2021","unstructured":"Park, W. J., Park, J. H., Cho, S. & Shin, M. G. Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999\u20132018. Blood Res. 56, 301\u2013314. https:\/\/doi.org\/10.5045\/br.2021.2021187 (2021).","journal-title":"Blood Res."},{"key":"9811_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. JAMA 327, 464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003 (2022).","journal-title":"JAMA"},{"key":"9811_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I. & Dimopoulos, M. A. Myeloma bone disease: From biology findings to treatment approaches. Blood 133, 1534\u20131539. https:\/\/doi.org\/10.1182\/blood-2018-11-852459 (2019).","journal-title":"Blood"},{"key":"9811_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082113","author":"S Rasch","year":"2020","unstructured":"Rasch, S. et al. Multiple myeloma associated bone disease. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12082113 (2020).","journal-title":"Cancers (Basel)"},{"key":"9811_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/leu.2010.62","volume":"24","author":"E Terpos","year":"2010","unstructured":"Terpos, E., Berenson, J., Cook, R. J., Lipton, A. & Coleman, R. E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24, 1043\u20131049. https:\/\/doi.org\/10.1038\/leu.2010.62 (2010).","journal-title":"Leukemia"},{"key":"9811_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/os.12267","volume":"8","author":"Surgeon\u2019s Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation","year":"2016","unstructured":"Surgeon\u2019s Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation. Consensus on surgical management of myeloma bone disease. Orthop. Surg. 8, 263\u2013269. https:\/\/doi.org\/10.1111\/os.12267 (2016).","journal-title":"Orthop. Surg."},{"key":"9811_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","volume":"16","author":"E Terpos","year":"2005","unstructured":"Terpos, E. & Dimopoulos, M. A. Myeloma bone disease: Pathophysiology and management. Ann. Oncol. 16, 1223\u20131231. https:\/\/doi.org\/10.1093\/annonc\/mdi235 (2005).","journal-title":"Ann. Oncol."},{"key":"9811_CR12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/rheumatology\/kez127","volume":"58","author":"G Nador","year":"2019","unstructured":"Nador, G. et al. Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures. Rheumatology (Oxford) 58, 1142\u20131153. https:\/\/doi.org\/10.1093\/rheumatology\/kez127 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"9811_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00198-021-06233-6","volume":"33","author":"G Agarwal","year":"2022","unstructured":"Agarwal, G. et al. Multiple myeloma screening within a fracture liaison service (FLS). Osteoporos. Int. 33, 937\u2013941. https:\/\/doi.org\/10.1007\/s00198-021-06233-6 (2022).","journal-title":"Osteoporos. Int."},{"key":"9811_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/s1470-2045(18)30072-x","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje, N. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 19, 370\u2013381. https:\/\/doi.org\/10.1016\/s1470-2045(18)30072-x (2018).","journal-title":"Lancet Oncol."},{"key":"9811_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21\u201333. https:\/\/doi.org\/10.4065\/78.1.21 (2003).","journal-title":"Mayo Clin. Proc."},{"key":"9811_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/jbmr.041131","volume":"20","author":"LJ Melton 3rd","year":"2005","unstructured":"Melton, L. J. 3rd., Kyle, R. A., Achenbach, S. J., Oberg, A. L. & Rajkumar, S. V. Fracture risk with multiple myeloma: A population-based study. J. Bone Miner. Res. 20, 487\u2013493. https:\/\/doi.org\/10.1359\/jbmr.041131 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"9811_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","volume":"105","author":"S Thorsteinsdottir","year":"2020","unstructured":"Thorsteinsdottir, S. et al. Fractures and survival in multiple myeloma: Results from a population-based study. Haematologica 105, 1067\u20131073. https:\/\/doi.org\/10.3324\/haematol.2019.230011 (2020).","journal-title":"Haematologica"},{"key":"9811_CR18","unstructured":"Ha, J. et al. J. Korean Med. Sci. (2023)."},{"key":"9811_CR19","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/s0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig, C., Knop, S. & Bornh\u00e4user, M. Multiple myeloma. Lancet 385, 2197\u20132208. https:\/\/doi.org\/10.1016\/s0140-6736(14)60493-1 (2015).","journal-title":"Lancet"},{"key":"9811_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000351895","volume":"18","author":"W Xiao","year":"2016","unstructured":"Xiao, W., Wang, Y., Pacios, S., Li, S. & Graves, D. T. Cellular and molecular aspects of bone remodeling. Front. Oral Biol. 18, 9\u201316. https:\/\/doi.org\/10.1159\/000351895 (2016).","journal-title":"Front. Oral Biol."},{"key":"9811_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3389\/fimmu.2017.00954","volume":"8","author":"A Mansour","year":"2017","unstructured":"Mansour, A., Wakkach, A. & Blin-Wakkach, C. Emerging roles of osteoclasts in the modulation of bone microenvironment and immune suppression in multiple myeloma. Front. Immunol. 8, 954. https:\/\/doi.org\/10.3389\/fimmu.2017.00954 (2017).","journal-title":"Front. Immunol."},{"key":"9811_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231\u20131234. https:\/\/doi.org\/10.1038\/nm.2452 (2011).","journal-title":"Nat. Med."},{"key":"9811_CR23","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole, K. E. et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J 19, 1842\u20131844. https:\/\/doi.org\/10.1096\/fj.05-4221fje (2005).","journal-title":"Faseb J"},{"key":"9811_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","volume":"39","author":"J Li","year":"2006","unstructured":"Li, J. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754\u2013766. https:\/\/doi.org\/10.1016\/j.bone.2006.03.017 (2006).","journal-title":"Bone"},{"key":"9811_CR25","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3803\/EnM.2021.1248","volume":"36","author":"E Jang","year":"2021","unstructured":"Jang, E., Ha, J., Baek, K. H. & Kang, M. I. Changes in Serum Dickkopf-1, RANK Ligand, osteoprotegerin, and bone mineral density after allogeneic hematopoietic stem cell transplantation treatment. Endocrinol. Metab. (Seoul) 36, 1211\u20131218. https:\/\/doi.org\/10.3803\/EnM.2021.1248 (2021).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"9811_CR26","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa030847 (2003).","journal-title":"N. Engl. J. Med."},{"key":"9811_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/blood.V128.22.484.484","volume":"128","author":"TN Trotter","year":"2016","unstructured":"Trotter, T. N. et al. Osteocyte apoptosis attracts myeloma cells to bone and supports progression through regulation of the bone marrow microenvironment. Blood 128, 484 (2016).","journal-title":"Blood"},{"key":"9811_CR28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani, N. et al. Increased osteocyte death in multiple myeloma patients: Role in myeloma-induced osteoclast formation. Leukemia 26, 1391\u20131401. https:\/\/doi.org\/10.1038\/leu.2011.381 (2012).","journal-title":"Leukemia"},{"key":"9811_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-020-6596-y","volume":"20","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Bone complications in patients with multiple myeloma in five European countries: A retrospective patient chart review. BMC Cancer 20, 170. https:\/\/doi.org\/10.1186\/s12885-020-6596-y (2020).","journal-title":"BMC Cancer"},{"key":"9811_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc, D. et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301, 513\u2013521. https:\/\/doi.org\/10.1001\/jama.2009.50 (2009).","journal-title":"JAMA"},{"key":"9811_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-9966-27-11","volume":"27","author":"M Sonmez","year":"2008","unstructured":"Sonmez, M. et al. Effect of pathologic fractures on survival in multiple myeloma patients: A case control study. J. Exp. Clin. Cancer Res. 27, 11. https:\/\/doi.org\/10.1186\/1756-9966-27-11 (2008).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"9811_CR32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1359\/jbmr.2003.18.7.1254","volume":"18","author":"T Jalava","year":"2003","unstructured":"Jalava, T. et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254\u20131260. https:\/\/doi.org\/10.1359\/jbmr.2003.18.7.1254 (2003).","journal-title":"J. Bone Miner. Res."},{"key":"9811_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1210\/jc.2013-2352","volume":"99","author":"YK Lee","year":"2014","unstructured":"Lee, Y. K., Lee, Y. J., Ha, Y. C. & Koo, K. H. Five-year relative survival of patients with osteoporotic hip fracture. J. Clin. Endocrinol. Metab. 99, 97\u2013100. https:\/\/doi.org\/10.1210\/jc.2013-2352 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"9811_CR34","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/s0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N. & Eisman, J. A. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353, 878\u2013882. https:\/\/doi.org\/10.1016\/s0140-6736(98)09075-8 (1999).","journal-title":"Lancet"},{"key":"9811_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.afos.2020.07.002","volume":"6","author":"M Rizkallah","year":"2020","unstructured":"Rizkallah, M. et al. Comparison of morbidity and mortality of hip and vertebral fragility fractures: Which one has the highest burden?. Osteoporos. Sarcopenia 6, 146\u2013150. https:\/\/doi.org\/10.1016\/j.afos.2020.07.002 (2020).","journal-title":"Osteoporos. Sarcopenia"},{"key":"9811_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2474-12-105","volume":"12","author":"J Panula","year":"2011","unstructured":"Panula, J. et al. Mortality and cause of death in hip fracture patients aged 65 or older: A population-based study. BMC Musculoskelet. Disord. 12, 105. https:\/\/doi.org\/10.1186\/1471-2474-12-105 (2011).","journal-title":"BMC Musculoskelet. Disord."},{"key":"9811_CR37","doi-asserted-by":"publisher","first-page":"215145932210838","DOI":"10.1177\/21514593221083825","volume":"13","author":"SH Lee","year":"2022","unstructured":"Lee, S. H. & Kim, K. U. Risk factors for postoperative pneumonia in the elderly following hip fracture surgery: A systematic review and meta-analysis. Geriatr. Orthop. Surg. Rehabil. 13, 21514593221083824. https:\/\/doi.org\/10.1177\/21514593221083825 (2022).","journal-title":"Geriatr. Orthop. Surg. Rehabil."},{"key":"9811_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bone.2019.07.023","volume":"127","author":"KE Kj\u00f8rholt","year":"2019","unstructured":"Kj\u00f8rholt, K. E., Kristensen, N. R., Prieto-Alhambra, D., Johnsen, S. P. & Pedersen, A. B. Increased risk of mortality after postoperative infection in hip fracture patients. Bone 127, 563\u2013570. https:\/\/doi.org\/10.1016\/j.bone.2019.07.023 (2019).","journal-title":"Bone"},{"key":"9811_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11914-017-0397-5","volume":"15","author":"C Panaroni","year":"2017","unstructured":"Panaroni, C., Yee, A. J. & Raje, N. S. Myeloma and bone disease. Curr. Osteoporos. Rep. 15, 483\u2013498. https:\/\/doi.org\/10.1007\/s11914-017-0397-5 (2017).","journal-title":"Curr. Osteoporos. Rep."},{"key":"9811_CR40","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/s1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 22, e119\u2013e130. https:\/\/doi.org\/10.1016\/s1470-2045(20)30559-3 (2021).","journal-title":"Lancet Oncol."},{"key":"9811_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10518","volume":"5","author":"H Lu","year":"2021","unstructured":"Lu, H., Pundole, X. & Lee, H. C. The role of bone-modifying agents in myeloma bone disease. JBMR Plus 5, e10518. https:\/\/doi.org\/10.1002\/jbm4.10518 (2021).","journal-title":"JBMR Plus"},{"key":"9811_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/jco.2017.76.6402","volume":"36","author":"K Anderson","year":"2018","unstructured":"Anderson, K. et al. Role of Bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice guideline update. J. Clin. Oncol. 36, 812\u2013818. https:\/\/doi.org\/10.1200\/jco.2017.76.6402 (2018).","journal-title":"J. Clin. Oncol."},{"key":"9811_CR43","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen, L. S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 7, 377\u2013387 (2001).","journal-title":"Cancer J."},{"key":"9811_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein, A. L. et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial. JAMA 317, 48\u201358. https:\/\/doi.org\/10.1001\/jama.2016.19425 (2017).","journal-title":"JAMA"},{"key":"9811_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4093\/dmj.2020.0207","volume":"44","author":"HK Kim","year":"2020","unstructured":"Kim, H. K., Song, S. O., Noh, J., Jeong, I. K. & Lee, B. W. Data configuration and publication trends for the Korean National Health Insurance and Health Insurance Review & Assessment Database. Diabetes Metab. J. 44, 671\u2013678. https:\/\/doi.org\/10.4093\/dmj.2020.0207 (2020).","journal-title":"Diabetes Metab. J."},{"key":"9811_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40, 373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8 (1987).","journal-title":"J. Chronic Dis."},{"key":"9811_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3803\/EnM.2023.102","volume":"38","author":"SW Cho","year":"2023","unstructured":"Cho, S. W. et al. Big data research in the field of endocrine diseases using the Korean National Health Information Database. Endocrinol. Metab. (Seoul) 38, 10\u201324. https:\/\/doi.org\/10.3803\/EnM.2023.102 (2023).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"9811_CR48","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e354","volume":"37","author":"D Park","year":"2022","unstructured":"Park, D. et al. Effects of socioeconomic status and residence areas on long-term survival in patients with early-onset dementia: The Korean National Health Insurance Service Database Study. J. Korean Med. Sci. 37, e354. https:\/\/doi.org\/10.3346\/jkms.2022.37.e354 (2022).","journal-title":"J. Korean Med. Sci."},{"key":"9811_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/bimj.200810488","volume":"51","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Some methods of propensity-score matching had superior performance to others: Results of an empirical investigation and Monte Carlo simulations. Biom. J. 51, 171\u2013184. https:\/\/doi.org\/10.1002\/bimj.200810488 (2009).","journal-title":"Biom. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09811-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T02:10:33Z","timestamp":1757297433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09811-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9811"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09811-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Seoul St. Mary\u2019s Hospital in Seoul, Korea (approval number: KC21ZNSI0448) and strictly adhered to the principles articulated in the Declaration of Helsinki, in addition to other relevant regulations and guidelines. Informed consent was waived owing to the retrorespective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"27321"}}